Search results for: 'biological solutions'

This study carries Frost & Sullivan’s observation of bone mineral density solutions in select Asian Countries (Australia, South Korea, and China); the regulatory trends for the same have been covered, highlighting the following: • Product registration and regulatory approval process details in select Asian countries (such as the Therapeutic Goods A...

The healthcare expenditure in Australia in the previous financial year was AUD 170.4 billion, with 10.3% of the gross domestic product (GDP), thereby allowing the country’s healthcare spending to pass the 10% mark for the first time. Healthcare expenditure continues to rise; however, the rate of increase has been curbed in the last few years. At AU...

The Asia-Pacific medical imaging and informatics market revenue is forecast to increase by 11.4% in 2023, mainly driven by the high procurement of medical imaging equipment and radiology IT solutions in the informatics sector. Large hospitals widely adopt digital radiography and ultrasound systems as the devices are operator-dependent and need a sk...

28 Apr 2017  |  Asia Pacific  |  Market Research

End-user and Decision-maker Survey of Southeast Asian PACS Market, Forecast to 2021

Revenue Opportunities Continue to Exist Even as Market Advances toward Vendor-neutral Solutions

Infographics

×

The research service provides an in-depth analysis of the Picture Archiving and Communication System (PACS) market across six Southeast Asian countries with a focus on end-user and radiology decision-maker needs, challenges, and vendor preferences. The study provides opportunity analysis, vendor landscape, and evolving technology and business model...

10 Jan 2018  |  Asia Pacific  |  Market Research

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...

With over-4000 pharmaceutical players, China is the second largest pharmaceutical industry globally. Although highly fragmented, global pharma and biopharmaceutical players such as Novartis, Novo Nordisk, and AstraZeneca, have a significant hold capturing at least 8-10Percentage of the market. The market being highly dependent on its distributor ne...

In this report, Frost & Sullivan analyzes emerging business models in the medical imaging industry in Asia-Pacific, focusing on India, Australia, Vietnam, Indonesia, and Singapore. Conventional business models that focus on selling products based on specification superiority or unique selling propositions are forecast to slow down. Requirement chan...

23 Mar 2017  |  Asia Pacific  |  Market Research

APAC Molecular Diagnostics Market, Forecast to 2021

Pharmerging Economies with Rising Healthcare Demands will Accentuate Growth

Infographics

×

The molecular diagnostics (MDx) market in APAC is witnessing rapid growth due to two main factors: the high adoption of MDx tests for infectious diseases applications in emerging countries, and the advent of innovative diagnostic solutions in cancer and NGS based solutions that are gaining pace in Asia. Multinational companies have not only identif...

Asia-Pacific represents the fastest growing region for healthcare information technology (healthcare IT) solutions across the world. Rapidly changing demographic factors coupled with fast-moving government policies and legislations are allowing advanced IT tools to penetrate the market. These tools have the potential to change existing healthcare p...